US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

20141,461 citationsJournal Articlebronze Open Access

Authors

Nadia Howlader · Louisiana State University Health Sciences Center New Orleans

Sean F. Altekruse · Louisiana State University Health Sciences Center New Orleans

Christopher I. Li · National Cancer Institute

Vivien W. Chen · Louisiana State University Health Sciences Center New Orleans

Christina A. Clarke · University of Washington

Lynn A. G. Ries · University of Washington

Kathleen A. Cronin

Abstract

In the future, SEER data can be used to monitor clinical outcomes in women diagnosed with different molecular subtypes of breast cancer for a large portion (approximately 28%) of the US population.

Topics & Keywords

Breast Cancer Treatment Studies HER2/EGFR in Cancer Research Cancer Risks and Factors

UN Sustainable Development Goals

No poverty

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 106, Issue 5

DOI: 10.1093/jnci/dju055

Field-Weighted Citation Impact: 22.78